Clinical Trials
92
Active:1
Completed:62
Trial Phases
5 Phases
Phase 1:61
Phase 2:4
Phase 3:16
+2 more phases
Drug Approvals
10
PHILIPPINES:10
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (91 trials with phase data)• Click on a phase to view related trials
Phase 1
61 (67.0%)Phase 3
16 (17.6%)Phase 4
8 (8.8%)Phase 2
4 (4.4%)Not Applicable
2 (2.2%)Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus
Not Applicable
Not yet recruiting
- Conditions
- Obesity &Amp; Overweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT07192263
A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients
Not Applicable
Not yet recruiting
- Conditions
- Mild to Moderate Atopic Dermatitis
- Interventions
- Drug: IN-115314 Ointment 1%Drug: IN-115314 Ointment 3%Drug: IN-115314 Ointment placebo
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 162
- Registration Number
- NCT07073677
This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants
Phase 1
Not yet recruiting
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Drug: IN-114199 10mg or placeboDrug: IN-114199 20mg or placeboDrug: IN-114199 2.5mg or placeboDrug: IN-114199 5mg or placeboDrug: IN-114199 40mg or placebo
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT06736912
- Locations
- 🇰🇷
Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of
To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers
Phase 1
Active, not recruiting
- Conditions
- Non-valvular Atrial Fibrillation (NVAF)
- Interventions
- Drug: IN-G00002
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT06725355
- Locations
- 🇰🇷
Central Hospital, Clinical Trial Center, Siheung, Korea, Republic of
Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
Recruiting
- Conditions
- Adjuvant Chemotherapy
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT06389552
- Locations
- 🇰🇷
Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
Dr. Reddy's Launches Next-Generation Acid Blocker Tegoprazan in India Following Phase III Success
Dr. Reddy's Laboratories has launched tegoprazan, a next-generation potassium-competitive acid blocker (PCAB), in India for treating acid peptic diseases including GERD and gastric ulcers.